Hemoglobin to creatinine ratio as a marker of the incomplete metabolic syndrome course

The significance of the hemoglobin to creatinine ratio (Hb/Cr) has not been studied in the context of metabolic syndrome. Correlations of this ratio remain undetermined. This obstacle made our study appropriate and relevant. Objective: to determine the hemoglobin to creatinine ratio and its correlations in patients with overweight and incomplete metabolic syndrome. Materials and methods. In compliance with the principles of the Helsinki Declaration of Human Rights and obtaining informed consent 197 patients (middle age 50.2 years old) from the Eden Medical Center (Lviv, Ukraine) were investigated. All of them had no complaints or clinical manifestations of internal organs diseases in the acute stage, did not take any medications on a regular basis, and considered themselves practically healthy. However, they had excess body weight and moderate lipid metabolism disorders. The results were processed using mathematical statistics, the data are presented as M±m; correlations were determined by Pearson-Spearman. The significance level was taken as p<0.05. Results. Among examined 197 patients the mean Hb/Cr ratio was 2.0. Patients with a value <2 had a worse state of purine and lipid metabolism, more pronounced inflammation and endogenous intoxication, and a tendency to thrombogenesis. Moreover, further decrease in the low Hb/Cr ratio was accompanied by endogenous intoxication activation according increased blood urea, by impaired glucose tolerance, and hyperglycemia with systemic inflammation activation. Conclusion. In patients with incomplete metabolic syndrome, a hemoglobin to creatinine ratio meaning less than 2.0 was associated with higher blood urea, impaired glucose tolerance, and hyperglycemia with activation of inflammation.

References

1. Zhang X.R., Zhong W.F., Liu R.Y. et al. (2025) Improved prediction and risk stratification of major adverse cardiovascular events using an explainable machine learning approach combining plasma biomarkers and traditional risk factors. Cardiovasc. Diabetol., 24(1): 153. doi: 10.1186/s12933-025-02711-x.
2. Li J., Wei X. (2025) Baseline and changes in cardiometabolic index and incident cardiovascular disease in two prospective cohorts. Am. J. Prev. Cardiol., 23: 101046. doi: 10.1016/j.ajpc.2025.101046.
3. Demir M., Kahraman F., Sen T., Astarcioglu M.A. (2023) The relationship of the hemoglobin to serum creatinine ratio with long-term mortality in patients with acute coronary syndrome: A retrospective study Medicine (Baltimore), 102(41): e35636. doi: 10.1097/MD.0000000000035636
4. Jang W., Lee M.H., Fujii N. et al. (2023) Soluble Apoptotic Biomarkers, Lipocalin-2, Proinflammatory Cytokines, and Reticulocyte Maturity Index in Anemia of Inflammation. Ann. Clin. Lab. Sci., 55(5): 672–681.
5. Wang X., Li R., You Y. et al. (2025) Obesity-aggravated erythrocyte injury in ischaemia-reperfusion: Interlinked oxidative stress, metabolic reprogramming, and cytoskeletal destabilisation. Life Sci., 380: 123975. doi: 10.1016/j.lfs.2025.123975.
6. Qin J.L., Zhao J., Chen Y.L. et al. (2026) Metabolic syndrome and diabetic kidney disease: a consistent dose-response association validated in an independent clinical cohort. Front Endocrinol (Lausanne), 16: 1724105. doi: 10.3389/fendo.2025.1724105.
7. Kang B., Zhang C., Li J., Chen L. (2025) Association between hemoglobin-to-creatinine ratio and all-cause mortality in patients with coronary artery disease. Egypt Heart J., 77(1): 109. doi: 10.1186/s43044-025-00707-2.
8. Ji W., Chen Y., Zhou H. et al. (2025) Prognostic value of hemoglobin to serum creatinine ratio in ST-elevation myocardial infarction: a secondary analysis based on a cohort study. BMC Cardiovasc Disord., 25(1): 394. doi: 10.1186/s12872-025-04856-9.
9. Meagher M.F., Cerrato C., Nguyen M.V. et al. (2025) Elevated creatinine-to-hemoglobin ratio is a novel preoperative marker for worsened survival outcomes in upper tract urothelial carcinoma: analysis from the ROBUUST registry. Minerva Urol. Nephrol., 77(6): 795–802. doi: 10.23736/S2724-6051.25.05498-9.
10. Marx-Schütt K., Cherney D.Z.I., Jankowski J. et al. (2025) Cardiovascular disease in chronic kidney disease. Eur. Heart J., 46(23): 2148–2160. doi: 10.1093/eurheartj/ehaf167.
11. Spadafora L., Cacciatore S., Galli M. et al. (2025) Hemoglobin-to-Creatinine Ratio Predicts One-Year Adverse Clinical Outcomes in ST-Elevation Myocardial Infarction: Retrospective and Propensity Score Matched Analysis. J. Clin. Med., 14(8): 2756. doi: 10.3390/jcm14082756.
12. Yanatori I., Nishina S., Kishi F., Hino K. (2023) Newly uncovered biochemical and functional aspects of ferritin. FASEB J., 37(8): e23095. doi: 10.1096/fj.202300918R.
13. Jiang Z.H., Lyu M.M., Feng Y.J. et al. (2025) Relationship between serum ferritin and the risk of all-cause death in patients with coronary artery disease. Clinics (Sao Paulo)., 80: 100772. doi: 10.1016/j.clinsp.2025.100772.
14. Chabrun F., Schwartz D., Gentile S. et al. (2026) Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0). Update in: Nat Med. doi: 10.1038/s41591-026-04304-x.
15. Wang D., Morton J.I., Salim A. et al. (2025) Association Between Diabetes and Anemia: Evidence From NHANES and the UK Biobank. Diabetes Care, 48(5): 816–826. doi: 10.2337/dc24-2535.
16. Çamci S., Kinik M., Ari S. et al. (2022) The predictive value of hemoglobin to creatinine ratio for contrast-induced nephropathy in percutaneous coronary interventions. Clin. Chem. Lab. Med., 60(9): 1455–1462. doi: 10.1515/cclm-2022-0247.
17. Abdullah K., Shahzad A., Javaid S. et al. (2025) Correlation Between Thyroid Hormone Profiles and Kidney Disease: Improving Global Outcomes (KDIGO) Risk Categories in Diabetic Kidney Disease Patients. Cureus, 17(4): e81781. doi: 10.7759/cureus.81781.
18. Li P., Wang Q., Yang Y., Ding Z. (2025) Autoimmune thyroid disease and human health: a systematic review of Mendelian randomization studies. Front. Immunol., 16: 1689498. doi: 10.3389/fimmu.2025.1689498.